Tonix Pharmaceuticals (TNXP) Competitors $34.93 -2.78 (-7.37%) As of 02:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNXP vs. AUPH, WVE, NAGE, MLYS, RCUS, SYRE, AKBA, ELVN, CVAC, and AVDLShould you be buying Tonix Pharmaceuticals stock or one of its competitors? The main competitors of Tonix Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Niagen Bioscience (NAGE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Enliven Therapeutics (ELVN), CureVac (CVAC), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Tonix Pharmaceuticals vs. Its Competitors Aurinia Pharmaceuticals Wave Life Sciences Niagen Bioscience Mineralys Therapeutics Arcus Biosciences Spyre Therapeutics Akebia Therapeutics Enliven Therapeutics CureVac Avadel Pharmaceuticals Tonix Pharmaceuticals (NASDAQ:TNXP) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking. Does the MarketBeat Community favor TNXP or AUPH? Aurinia Pharmaceuticals received 235 more outperform votes than Tonix Pharmaceuticals when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 60.53% of users gave Tonix Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTonix PharmaceuticalsOutperform Votes34260.53% Underperform Votes22339.47% Aurinia PharmaceuticalsOutperform Votes57773.41% Underperform Votes20926.59% Which has more risk & volatility, TNXP or AUPH? Tonix Pharmaceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Which has preferable earnings & valuation, TNXP or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals. Tonix Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTonix Pharmaceuticals$10.04M25.48-$116.66M-$1.96 thousand-0.02Aurinia Pharmaceuticals$247.30M4.51-$78.02M$0.2829.50 Do insiders and institutionals hold more shares of TNXP or AUPH? 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 0.0% of Tonix Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor TNXP or AUPH? In the previous week, Tonix Pharmaceuticals had 5 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 14 mentions for Tonix Pharmaceuticals and 9 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Tonix Pharmaceuticals' score of 0.51 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tonix Pharmaceuticals 3 Very Positive mention(s) 6 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate TNXP or AUPH? Tonix Pharmaceuticals currently has a consensus target price of $585.00, suggesting a potential upside of 1,574.78%. Aurinia Pharmaceuticals has a consensus target price of $11.50, suggesting a potential upside of 39.23%. Given Tonix Pharmaceuticals' higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tonix Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TNXP or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of -10.23% compared to Tonix Pharmaceuticals' net margin of -1,197.86%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Tonix Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tonix Pharmaceuticals-1,197.86% -163.95% -118.88% Aurinia Pharmaceuticals -10.23%-4.41%-3.07% SummaryAurinia Pharmaceuticals beats Tonix Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Tonix Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNXP vs. The Competition Export to ExcelMetricTonix PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.86M$6.94B$5.60B$8.62BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-0.018.8427.2520.00Price / Sales25.48265.40413.35158.30Price / CashN/A65.8538.2534.64Price / Book0.016.617.124.70Net Income-$116.66M$144.20M$3.24B$248.14M7 Day Performance-9.06%4.00%2.71%2.48%1 Month Performance82.02%11.33%8.93%6.15%1 Year Performance-68.53%3.91%31.30%13.59% Tonix Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNXPTonix Pharmaceuticals3.3496 of 5 stars$34.93-7.4%$585.00+1,574.8%-82.3%$255.86M$10.04M-0.0150News CoverageGap DownAUPHAurinia Pharmaceuticals3.3362 of 5 stars$8.17-0.3%$11.50+40.8%+45.8%$1.10B$247.30M-54.45300Positive NewsAnalyst RevisionWVEWave Life Sciences4.4461 of 5 stars$7.05-2.4%$21.17+200.4%+16.0%$1.08B$104.94M-6.34240News CoveragePositive NewsAnalyst ForecastAnalyst RevisionNAGENiagen Bioscience1.4834 of 5 stars$13.44+3.8%$18.00+33.9%N/A$1.06B$107.93M79.06120News CoverageAnalyst ForecastMLYSMineralys Therapeutics3.0564 of 5 stars$16.09-0.2%$38.00+136.2%+19.7%$1.05BN/A-4.4228Positive NewsAnalyst ForecastRCUSArcus Biosciences2.5538 of 5 stars$9.81-1.6%$24.13+145.9%-41.9%$1.04B$141M-3.12500Options VolumeAnalyst RevisionSYRESpyre Therapeutics2.392 of 5 stars$17.18+1.2%$53.40+210.8%-52.6%$1.03B$890K-2.2973Positive NewsAKBAAkebia Therapeutics4.4668 of 5 stars$3.87-2.6%$6.75+74.6%+221.6%$1.01B$184.91M-16.72430News CoverageELVNEnliven Therapeutics2.4871 of 5 stars$20.49-1.2%$37.25+81.8%-10.9%$1.01BN/A-10.7850Insider TradeCVACCureVac4.4809 of 5 stars$4.44+0.6%$11.00+148.0%-4.2%$994.94M$523.70M8.06880Trending NewsOptions VolumeGap UpAVDLAvadel Pharmaceuticals2.166 of 5 stars$10.21+5.0%$19.43+90.4%-35.2%$987.22M$194.45M-12.9270Analyst RevisionGap Up Related Companies and Tools Related Companies Aurinia Pharmaceuticals Alternatives Wave Life Sciences Alternatives Niagen Bioscience Alternatives Mineralys Therapeutics Alternatives Arcus Biosciences Alternatives Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives Enliven Therapeutics Alternatives CureVac Alternatives Avadel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNXP) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tonix Pharmaceuticals Holding Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tonix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
